Vaccinex, Inc. (VCNX): Price and Financial Metrics
VCNX Price/Volume Stats
| Current price | $0.74 | 52-week high | $1.40 |
| Prev. close | $0.75 | 52-week low | $0.25 |
| Day low | $0.74 | Volume | 100 |
| Day high | $0.74 | Avg. volume | 4,046 |
| 50-day MA | $0.89 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 1.92M |
VCNX Stock Price Chart Interactive Chart >
Vaccinex, Inc. (VCNX) Company Bio
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.
VCNX Price Returns
| 1-mo | 29.73% |
| 3-mo | -30.19% |
| 6-mo | -72.89% |
| 1-year | -84.77% |
| 3-year | -40.80% |
| 5-year | -79.61% |
| YTD | -24.49% |
| 2024 | 47.41% |
| 2023 | 3.15% |
| 2022 | -38.03% |
| 2021 | -49.76% |
| 2020 | -57.32% |
Continue Researching VCNX
Want to do more research on Vaccinex Inc's stock and its price? Try the links below:Vaccinex Inc (VCNX) Stock Price | Nasdaq
Vaccinex Inc (VCNX) Stock Quote, History and News - Yahoo Finance
Vaccinex Inc (VCNX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...